Next Article in Journal
A Mouse Model to Assess STAT3 and STAT5A/B Combined Inhibition in Health and Disease Conditions
Next Article in Special Issue
Papillary Renal Cell Carcinomas Rewire Glutathione Metabolism and Are Deficient in Both Anabolic Glucose Synthesis and Oxidative Phosphorylation
Previous Article in Journal
Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers
Previous Article in Special Issue
MiT Family Translocation Renal Cell Carcinoma: from the Early Descriptions to the Current Knowledge

The Changing Therapeutic Landscape of Metastatic Renal Cancer

Departamento Clínico, Facultad de Ciencias Biomédicas, Universidad Europea de Madrid, Hospital Universitario de Getafe, Carretera de Toledo km 12.5, Getafe, 28043 Madrid, Spain
SUNY Upstate Medical University, Upstate University Hospital, Syracuse, NY 13210, USA
Author to whom correspondence should be addressed.
Cancers 2019, 11(9), 1227;
Received: 23 July 2019 / Revised: 19 August 2019 / Accepted: 19 August 2019 / Published: 22 August 2019
(This article belongs to the Special Issue Renal Cell Carcinoma)
The practising clinician treating a patient with metastatic clear cell renal cell carcinoma (CCRCC) faces a difficult task of choosing the most appropriate therapeutic regimen in a rapidly developing field with recommendations derived from clinical trials. NCCN guidelines for kidney cancer initiated a major shift in risk categorization and now include emerging treatments in the neoadjuvant setting. Updates of European Association of Urology clinical guidelines also include immune checkpoint inhibition as the first-line treatment. Randomized trials have demonstrated a survival benefit for ipilimumab and nivolumab combination in the intermediate and poor-risk group, while pembrolizumab plus axitinib combination is recommended not only for unfavorable disease but also for patients who fit the favorable risk category. Currently vascular endothelial growth factor (VEGF) targeted therapy based on tyrosine kinase inhibitors (TKI), sunitinib and pazopanib is the alternative regimen for patients who cannot tolerate immune checkpoint inhibitors (ICI). Cabozantinib remains a valid alternative option for the intermediate and high-risk group. For previously treated patients with TKI with progression, nivolumab, cabozantinib, axitinib, or the combination of ipilimumab and nivolumab appear the most plausible alternatives. For patients previously treated with ICI, any VEGF-targeted therapy, not previously used in combination with ICI therapy, seems to be a valid option, although the strength of this recommendation is weak. The indication for cytoreductive nephrectomy (CN) is also changing. Neoadjuvant systemic therapy does not add perioperative morbidity and can help identify non-responders, avoiding unnecessary surgery. However, the role of CN should be investigated under the light of new immunotherapeutic interventions. Also, markers of response to ICI need to be identified before the optimal selection of therapy could be determined for a particular patient. View Full-Text
Keywords: renal cell carcinoma; immune checkpoint inhibitors; tyrosine kinase inhibitors; efficacy; toxicity; cytoreductive nephrectomy renal cell carcinoma; immune checkpoint inhibitors; tyrosine kinase inhibitors; efficacy; toxicity; cytoreductive nephrectomy
Show Figures

Figure 1

MDPI and ACS Style

Angulo, J.C.; Shapiro, O. The Changing Therapeutic Landscape of Metastatic Renal Cancer. Cancers 2019, 11, 1227.

AMA Style

Angulo JC, Shapiro O. The Changing Therapeutic Landscape of Metastatic Renal Cancer. Cancers. 2019; 11(9):1227.

Chicago/Turabian Style

Angulo, Javier C., and Oleg Shapiro. 2019. "The Changing Therapeutic Landscape of Metastatic Renal Cancer" Cancers 11, no. 9: 1227.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop